Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua J Neumiller

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Clinical Diabetes : a Publication of the American Diabetes Association|February 4, 2015
Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetesJoshua J Neumiller
The Medical Clinics of North America|December 3, 2014
Incretin-based therapiesJoshua J Neumiller
Diabetes Spectrum : a Publication of the American Diabetes Association|February 17, 2025
Meeting People Where They Are: Improving Diabetes Care and Outcomes Through Education and CollaborationJoshua J Neumiller
Clinical Therapeutics|June 14, 2011
Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatmentJoshua J Neumiller
The Annals of Pharmacotherapy|February 10, 2012
Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitusJoshua J Neumiller
Journal of the American Pharmacists Association : Japha|October 6, 2009
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitorsJoshua J Neumiller
Cardiovascular & Hematological Agents in Medicinal Chemistry|July 26, 2012
Incretin pharmacology: a review of the incretin effect and current incretin-based therapiesJoshua J Neumiller
Drugs in Context|July 4, 2014
Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetesJoshua J Neumiller
Clinical Therapeutics|March 24, 2012
Review of linagliptin for the treatment of type 2 diabetes mellitusJoshua J Neumiller, Stephen M Setter
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 14, 2010
Technosphere insulin: an inhaled prandial insulin productJoshua J Neumiller, R Keith Campbell
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Clinical Diabetes : a Publication of the American Diabetes Association|February 4, 2015
Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetesJoshua J Neumiller
The Medical Clinics of North America|December 3, 2014
Incretin-based therapiesJoshua J Neumiller
Diabetes Spectrum : a Publication of the American Diabetes Association|February 17, 2025
Meeting People Where They Are: Improving Diabetes Care and Outcomes Through Education and CollaborationJoshua J Neumiller
Clinical Therapeutics|June 14, 2011
Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatmentJoshua J Neumiller
The Annals of Pharmacotherapy|February 10, 2012
Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitusJoshua J Neumiller
Journal of the American Pharmacists Association : Japha|October 6, 2009
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitorsJoshua J Neumiller
Cardiovascular & Hematological Agents in Medicinal Chemistry|July 26, 2012
Incretin pharmacology: a review of the incretin effect and current incretin-based therapiesJoshua J Neumiller
Drugs in Context|July 4, 2014
Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetesJoshua J Neumiller
Clinical Therapeutics|March 24, 2012
Review of linagliptin for the treatment of type 2 diabetes mellitusJoshua J Neumiller, Stephen M Setter
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 14, 2010
Technosphere insulin: an inhaled prandial insulin productJoshua J Neumiller, R Keith Campbell
Pageof 11